Literature DB >> 10560351

A national audit of the laboratory diagnosis of tuberculosis and other mycobacterial diseases within the United Kingdom.

F A Drobniewski1, B Watt, E G Smith, J G Magee, R Williams, J Holder, J Ostrowski.   

Abstract

In order to audit United Kingdom laboratory diagnostic and reference services including novel molecular methods for tuberculosis, a questionnaire was sent to laboratories submitting specimens to the PHLS Mycobacterium Reference Unit (MRU) and regional centres and to the Scottish Mycobacteria Reference Laboratory (SMRL) in 1996-7. Nationally, 67.2% of laboratories responded. Most UK laboratories were fully or conditionally CPA accredited and take part in the NEQAS proficiency scheme. On average only 3.3% of primary samples submitted for mycobacterial diagnosis in 1995 produced a mycobacterial culture from approximately half as many patients (that is, a mean of 1488 specimens producing 49 isolates from 23 patients). Potentially over 380,000 specimens are processed for mycobacteria in the UK each year. The majority of laboratories use 4% NaOH +/- NALC for specimen decontamination. Culture on solid media was used by most laboratories and 62.9% also use liquid media. Most laboratories incubated cultures for eight weeks. Few laboratories use molecular diagnostic methods. Laboratories were most likely to use molecular methods for diagnosing tuberculous meningitis and for specimens from immunocompromised patients, although usage was strongly influenced by cost. Within England and Wales 43.9% (47/107) and 56% (61/109) of laboratories wanted a rapid service for rifampicin resistance detection in M tuberculosis from immunocompetent and immunocompromised patients, respectively. In regard to a tuberculous meningitis service, 80.5% (43/112) and 84.3% (102/121) of laboratories wanted this service for immunocompetent and immunocompromised patients, respectively. The quality of reference services was rated as "very good"/"good" by 85.6% of respondents nationally. Rapid molecular amplification diagnostic services were established at the PHLS MRU for rifampicin drug resistance detection nationally and for tuberculous meningitis at the MRU.

Entities:  

Mesh:

Year:  1999        PMID: 10560351      PMCID: PMC1023066          DOI: 10.1136/jcp.52.5.334

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  8 in total

1.  Reactivity and assay restriction profiles of monoclonal and polyclonal antibodies to acid phosphatases: a preliminary study.

Authors:  H Bull; M Choy; I Manyonda; C A Brown; E E Waldron; S D Holmes; J C Booth; P N Nelson
Journal:  Immunol Lett       Date:  1999-12-01       Impact factor: 3.685

Review 2.  Tuberculosis in developing countries: burden, intervention and cost.

Authors:  C J Murray; K Styblo; A Rouillon
Journal:  Bull Int Union Tuberc Lung Dis       Date:  1990-03

3.  Tuberculosis in England and Wales in 1993: results of a national survey. Public Health Laboratory Service/British Thoracic Society/Department of Health Collaborative Group.

Authors:  D Kumar; J M Watson; A Charlett; S Nicholas; J H Darbyshire
Journal:  Thorax       Date:  1997-12       Impact factor: 9.139

4.  Tuberculosis: a global overview of the situation today.

Authors:  P Sudre; G ten Dam; A Kochi
Journal:  Bull World Health Organ       Date:  1992       Impact factor: 9.408

5.  Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic.

Authors:  M C Raviglione; D E Snider; A Kochi
Journal:  JAMA       Date:  1995-01-18       Impact factor: 56.272

6.  Secular trends of tuberculosis in western Europe.

Authors:  M C Raviglione; P Sudre; H L Rieder; S Spinaci; A Kochi
Journal:  Bull World Health Organ       Date:  1993       Impact factor: 9.408

7.  Global tuberculosis incidence and mortality during 1990-2000.

Authors:  P J Dolin; M C Raviglione; A Kochi
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

8.  Geographical distribution of tuberculosis notifications in national surveys of England and Wales in 1988 and 1993: report of the Public Health Laboratory Service/British Thoracic Society/Department of Health Collaborative Group.

Authors:  L P Ormerod; A Charlett; C Gilham; J H Darbyshire; J M Watson
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

  8 in total
  8 in total

Review 1.  Modern laboratory diagnosis of mycobacterial infections.

Authors:  S A Watterson; F A Drobniewski
Journal:  J Clin Pathol       Date:  2000-10       Impact factor: 3.411

2.  Identifying sputum specimens of high priority for examination by enhanced mycobacterial detection, identification, and susceptibility systems (EMDISS) to promote the rapid diagnosis of infectious pulmonary tuberculosis.

Authors:  R Freeman; J Magee; A Barrett
Journal:  J Clin Pathol       Date:  2001-08       Impact factor: 3.411

3.  Cost-effectiveness analysis of the gen-probe amplified mycobacterium tuberculosis direct test as used routinely on smear-positive respiratory specimens.

Authors:  David W Dowdy; Amelia Maters; Nicole Parrish; Christopher Beyrer; Susan E Dorman
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

4.  Impact of GeneXpert MTB/RIF on patients and tuberculosis programs in a low-burden setting. a hypothetical trial.

Authors:  J Lucian Davis; L Masae Kawamura; Lelia H Chaisson; Jennifer Grinsdale; Jihane Benhammou; Christine Ho; Anna Babst; Houmpheng Banouvong; John Z Metcalfe; Mark Pandori; Philip C Hopewell; Adithya Cattamanchi
Journal:  Am J Respir Crit Care Med       Date:  2014-06-15       Impact factor: 21.405

5.  Significance of Fas and Fas ligand in tuberculous lymphadenitis.

Authors:  Tehmina Mustafa; Stanley J Mogga; Sayoki G M Mfinanga; Odd Mørkve; Lisbet Sviland
Journal:  Immunology       Date:  2005-02       Impact factor: 7.397

6.  Identification of rifampin-resistant Mycobacterium tuberculosis strains by hybridization, PCR, and ligase detection reaction on oligonucleotide microchips.

Authors:  V Mikhailovich; S Lapa; D Gryadunov; A Sobolev; B Strizhkov; N Chernyh; O Skotnikova; O Irtuganova; A Moroz; V Litvinov; M Vladimirskii; M Perelman; L Chernousova; V Erokhin; A Zasedatelev; A Mirzabekov
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

7.  External Quality Assessment for Tuberculosis Diagnosis and Drug Resistance in the European Union: A Five Year Multicentre Implementation Study.

Authors:  Vladyslav Nikolayevskyy; Doris Hillemann; Elvira Richter; Nada Ahmed; Marieke J van der Werf; Csaba Kodmon; Francis Drobniewski; Sabine Ruesch-Gerdes
Journal:  PLoS One       Date:  2016-04-07       Impact factor: 3.240

8.  Rapid molecular testing for TB to guide respiratory isolation in the U.S.: a cost-benefit analysis.

Authors:  Alexander J Millman; David W Dowdy; Cecily R Miller; Robert Brownell; John Z Metcalfe; Adithya Cattamanchi; J Lucian Davis
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.